

Resource Summary Report

Generated by [dkNET](#) on Aug 13, 2026

C57BL/10-Rim5/Rim5

RRID:IMSR_NIG:236

Type: Organism

Proper Citation

RRID:IMSR_NIG:236

Organism Information

URL: <http://www.shigen.nig.ac.jp/mouse/nig/resource/detail/236>

Proper Citation: RRID:IMSR_NIG:236

Description: Mus musculus with name C57BL/10-Rim5/Rim5 from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; mutant stock:

Catalog Number: NIG:236

Database: National Institute of Genetics

Database Abbreviation: NIG

Availability: embryo

Organism Name: C57BL/10-Rim5/Rim5

Record Creation Time: 20250513T061856+0000

Record Last Update: 20260808T055319+0000

Ratings and Alerts

No rating or validation information has been found for C57BL/10-Rim5/Rim5.

No alerts have been found for C57BL/10-Rim5/Rim5.

Data and Source Information

Source: [Integrated Animals](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. *Molecular cancer therapeutics*, 25(4), 635.

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. *iScience*, 29(6), 116184.

Savani MR, et al. (2026) Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice. *Nature metabolism*, 8(5), 1124.

Favours E, et al. (2026) Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3031.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. *Cancer research*, 85(22), 4380.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR α -Targeted TOP1i-Loaded ADC, for the Treatment of FR α -Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5261.

Savani MR, et al. (2025) Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice. *bioRxiv : the preprint server for biology*.

Guillorit H, et al. (2025) Streptomycin targets tumor-initiating cells by disrupting oxidative phosphorylation. *Cell chemical biology*, 32(4), 570.

Dahiya UR, et al. (2025) Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer. *Cell reports*, 44(9), 116235.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. *Cancer research communications*, 5(4), 719.

Lin C, et al. (2025) Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. *Cell reports*, 44(6), 115792.

Wang Z, et al. (2024) Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. *Nature communications*, 15(1), 2073.

Zhang D, et al. (2024) Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs. *Communications medicine*, 4(1), 87.

Chang Y, et al. (2024) Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. *Cell reports. Medicine*, 5(10), 101752.

Staniszewska AD, et al. (2024) Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1338.

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. *Cancer cell*, 42(8), 1336.

Anselmino N, et al. (2024) Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2272.

Cerutti C, et al. (2024) IQGAP1 and NWASP promote human cancer cell dissemination and metastasis by regulating α 1-integrin via FAK and MRTF/SRF. *Cell reports*, 43(4), 113989.

Sconocchia G, et al. (2022) Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment. *Life science alliance*, 5(12).